tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Cabaletta Bio: Strong Financial Position and Strategic Clinical Advancements Drive Buy Rating
PremiumRatingsCabaletta Bio: Strong Financial Position and Strategic Clinical Advancements Drive Buy Rating
2M ago
Cabaletta Bio’s Promising Clinical Study on CABA-201 for Myasthenia Gravis
Premium
Company Announcements
Cabaletta Bio’s Promising Clinical Study on CABA-201 for Myasthenia Gravis
2M ago
Cabaletta Bio files $240M mixed securities shelf
Premium
The Fly
Cabaletta Bio files $240M mixed securities shelf
2M ago
Cabaletta Bio’s RESET-MG Study: A Potential Game-Changer for Myasthenia Gravis Treatment
PremiumCompany AnnouncementsCabaletta Bio’s RESET-MG Study: A Potential Game-Changer for Myasthenia Gravis Treatment
3M ago
Cabaletta Bio’s RESET-Myositis Study: A Promising Step in Autoimmune Treatment
Premium
Company Announcements
Cabaletta Bio’s RESET-Myositis Study: A Promising Step in Autoimmune Treatment
3M ago
Cabaletta Bio’s RESET-MG Study: A Promising Step in Myasthenia Gravis Treatment
Premium
Company Announcements
Cabaletta Bio’s RESET-MG Study: A Promising Step in Myasthenia Gravis Treatment
3M ago
Promising Efficacy and Strategic Advancements: Douglas Tsao’s Buy Rating on Cabaletta Bio
PremiumRatingsPromising Efficacy and Strategic Advancements: Douglas Tsao’s Buy Rating on Cabaletta Bio
4M ago
Cabaletta presents ‘promising’ results across indications, says H.C. Wainwright
Premium
The Fly
Cabaletta presents ‘promising’ results across indications, says H.C. Wainwright
4M ago
Cabaletta Bio Ends Sales Agreement with TD Securities
Premium
Company Announcements
Cabaletta Bio Ends Sales Agreement with TD Securities
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100